

FINDINGS OF THE PULMOCORE COMPREHENSIVE PANEL

Positive Biomarkers:

Marker	Biological Association	Test	Result	Therapies approved in Lung adenocarcinoma	Therapies approved in other indications	May indicate resistance to therapies	Trials
ALK	ALK	MUTN (seq)	EML4-ALK fusion	Ceritinib, Brigatinib, Alectinib, Crizotinib	None	No	Yes

Laboratory Technical Data:

Variant	Variant Allele Frequency	Coding Sequence Change
ALK-EML4-ALK fusion	0.7%	EML4-ALK fusion

CTC Data:

CTCs Detected (Count)	5
PD-L1 Positive CTCs (Count)	1
Percentage of PD-L1 Positive CTCs	20%

Comments: Less than 50% of PD-L1 positive CTCs has been correlated with <50% PD-L1 expression by immunohistochemistry on tissue.